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Multinutrient Supplementation for Prevention
of Major Depressive Disorder in Overweight Adults
To the Editor The MooDFOOD randomized clinical trial1 found
that neither multinutrient supplementation nor food-related
behavioral activation therapy reduced major depressive dis-
order episodes in overweight or obese adults with depressive
symptoms. However, the low rate of conversion to major de-
pressive disorder of only 10% after 12 months vs 33% ex-
pected means that the study was likely underpowered, and the
interpretation that nutrients “showed no effect” was poten-
tially incorrect.
The authors discussed various single-nutrient studies
showing no benefit in the treatment of depression before
concluding that micronutrients are unlikely candidates for
prevention. These are different questions. Meta-analyses
show that omega-3 eicosapentaenoic fatty acid supplements
can be effective in treating major depressive disorder but not
subclinical depressive symptoms.2 For prevention, including
approximately 1 g of eicosapentaenoic fatty acid in the
MooDFOOD supplementation was thus a reasonable choice.
We also query the choice of other nutrients, only 2 vita-
mins and 2 minerals at dosages below the recommended di-
etary allowance (400 μg of folic acid, 20 μg of vitamin D, 30 μg
of selenium, 100 mg of calcium). This choice does not reflect
current knowledge with respect either to specific nutrients most
strongly implicated in depression3 and doses required or to the
importance of combining a wide range of micronutrients at lev-
els likely to confer benefits for optimal brain function and im-
prove oxidative stress and inflammation.4,5
Another limitation the authors highlighted is the lack of
any nutritional status measures. Costs and other practicali-
ties make including such measures difficult, but without them,
meaningful conclusions cannot be drawn. Before treatment,
did these participants actually lack the nutrients that were sup-
plied? If so, did supplementation normalize those deficien-
cies? Equally important, did they lack other nutrients not pro-
vided? Whenever individualized treatment is impractical, an
overinclusive approach (within safe limits) to both nutrients
and dosages seems preferable to risking some deficiencies re-
maining unaddressed.4
Overweight and obesity may affect both nutrient status
and requirements and mood, so the high body mass index of
this sample would limit generalization of any findings to
other populations. Unfortunately, overall findings were
inconclusive—although depression, anxiety, and health mea-
sures improved on average in all groups, suggesting trial par-
ticipation itself was beneficial. Given the high prevalence and
costs of depression, limitations of existing treatments, and
evidence implicating nutritional factors, further large-scale,
high-quality trials of both diet and supplement interventions
are warranted.
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In Reply Although the MooDFOOD trial1 was, to our knowl-
edge, the largest trial to date investigating 2 nutritional strat-
egies for the prevention of depression in 1025 participants,
we are aware of the limitations raised by Drs Rucklidge and
Richardson, which were addressed in the article. The power
of our trial for development of depressive disorder might
have been limited, but—in contrast to the food-related behav-
ioral intervention therapy—we did not find any indication for
a preventive effect of the nutrient supplement on either epi-
sodes of depression or depressive symptoms. Placebo even
outperformed supplements in their effects on both depres-
sive and anxiety symptoms. Thus, we stand with our conclu-
sion that these findings do not support the use of the tested
interventions for prevention of major depressive disorder in
this population.
The MooDFOOD intervention trial investigated the pre-
vention of depression, not treatment. Unfortunately, it is dif-
ficult to perform a large-scale study with adequate power and
a clinical outcome, so there are not many trials investigating
the effect of nutrition or nutrients on the prevention of
depression. Only 1 randomized clinical trial2 on omega-3
supplementation involving mild to moderately depressed
individuals was mentioned in the article because we consid-
ered that sample somewhat comparable with our study
sample. This trial did not show a favorable effect of omega-3
polyunsaturated fatty acids either. Rucklidge and Richardson
suggest the beneficial effects of omega-3 fatty acids in treat-
ment based on results from a meta-analysis.3 However, effect
sizes vary, and many studies are small; therefore, clinical rel-
evance is arguable. Furthermore, evidence from the same
trials was interpreted differently in a Cochrane analysis.4
For most nutrients, there is simply not enough evidence to
come to a valid conclusion on the efficacy in the treatment
of depression.
With type and dosage of supplements, we took a prag-
matic approach in combining several promising nutrients based
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on the state-of-the-art scientific literature in 2014, when the
study started.5 We chose dosages that were reported to be ef-
fective in some individual studies, but we also chose dosages
that were unlikely to harm any participants because nutri-
tional supplements have also been shown to have negative
health effects.6
Rucklidge and Richardson refer to the lack of nutritional
data in the study. However, we obtained blood samples to de-
termine nutrient status at baseline and during follow-up from
approximately 67% of our sample. We are currently using these
data to test whether participants with lower nutrient levels at
baseline are more likely to benefit from the nutrient supple-
ment than participants with higher levels, and to assess the
effect of change in nutrient status during treatment on treat-
ment effect. These explorative analyses will inform the opti-
mal development of future trials focusing on the role of nu-
trition in the prevention of depression.
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Collaborative Care for Adults With Obesity
and Depression
To the Editor The study by Dr Ma and colleagues1 tested
an integrated collaborative care intervention for adults
with comorbid depression and obesity. In the intervention
group, behavioral-psychological therapy was typically
combined with antidepressants, supported by weekly to
monthly sessions. As such, the low rate of sustained depres-
sion response of 29% for participants in the intervention
group and 22% for participants in the usual care group at 12
months warrants further scrutiny.
Recruitment for depression was based on a score of 10 or
higher on the self-reported 9-item Patient Health Question-
naire 9 (PHQ-9), and patients did not undergo a diagnostic in-
terview for depression. Although acceptable in other popula-
tions, the specificity of this approach in populations with
obesity is poorer, such that up to 50% of those recruited may
not have had clinical depression.2,3
In this context, it is striking that 41% of the study popula-
tion had a diagnosis of binge eating disorder, and in these pa-
tients there was no difference between treatment groups on
either co-primary outcome. Binge eating disorder is a feasible
barrier to collaborative care for several reasons. First, com-
mon symptoms of binge eating disorder, including overeat-
ing, low mood, and feelings of guilt,4 are likewise captured by
the depression measures used in the study to define inclu-
sion (PHQ-9) and primary response (20-item Depression Symp-
tom Checklist [SCL-20]).
Second, optimum treatment for binge eating disorder
typically requires specific, high-intensity psychological
therapies beyond the current collaborative care interven-
tion, such as extended, modified cognitive behavioral
therapy or dialectical behavioral therapy.4 Antidepressants
produce limited benefit on weight or depression in pa-
tients with binge eating disorder.4 The stimulant lisdexam-
fetamine is the only current pharmacotherapy approved
by the US Food and Drug Administration for binge eat-
ing disorder.5
Third, comorbid substance use and personality disorder,
which are known barriers to depression treatment, are over-
represented in individuals with binge eating disorder.4 Col-
lectively, this suggests that binge eating disorder, either as
a false-positive for depression or as a comorbidity, could have
limited both weight loss and the number of patients achiev-
ing persistent depression response.
For future collaborative care of depressed patients with
obesity, a more rigorous diagnosis of depression (through di-
agnostic interview or higher PHQ-9 cutoff score) would re-
duce the risk of patients with binge eating disorder being falsely
categorized as having depression. For those with depression
and comorbid binge eating disorder, either such patients should
be excluded and directed toward higher-intensity treatments
for binge eating disorder, or the intervention should be adapted
to integrate such treatment.
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